News & Analysis on Pharmaceutical Technology & Manufacturing
People on the Move: Pharma Jobs
By Dan Stanton
- Last updated on
Dr. Jackie Hunter CBE - Image c/o Max Alexander
We begin this week with British Government funded bioscience research and training company BBSRC who has appointed Dr. Jackie Hunter CBE as its next Chief Executive.
Hunter spent thirty years working in the pharmaceutical sector, including several years developing and leading GSK's external science engagement strategy and is also founder of OI Pharma.
Chair of BBSRC Council Prof Sir Tom Blundell said: “She has an enviable track record of success in innovation in the bioscience sector and, crucially in the current climate, of working closely with partners to deliver a common vision and successful outcomes.”
Sticking with biopharmaceuticals, clinical stage biotech company Kite Pharma has appointed Dr. Keith Nolop as Chief Medical Officer.
Having come from being Senior Vice President of Development and Chief Medical Officer at Plexxikon and with over 2o years of experience, “Dr. Nolop's vast experience in drug development from conception to approval will be instrumental to advancing Kite's eACT products through multi-center clinical trials and on to registration,” said Kite CEO Dr. Aya Jakobovits.
Sucampo Pharmaceuticals has announced Kei Tolliver - executive vice president at S&R Technology Holdings - has been elected to its board.
CEO Dr. Ryuji Ueno said: “Kei brings to Sucampo’s Board a deep knowledge of our company’s products as well as global experience. We believe that this expertise will provide value to Sucampo and our shareholders as we focus on the growth of our business and the further development of our pipeline.”
Friday is upon us so here's one from our archives: Singapore's Government's launch of training courses for clinical researchers:
Over to Texas, and Mirna Therapeutics has got a new Vice President of Oncology and Chief Medical Officer in the form of Dr. Sinil Kim.
Kim, most recently a Senior Director at Pfizer and prior to that Director of Clinical Oncology at Bristol-Myers Squibb, will be responsible for directing clinical development of MRX34, Mirna’s first cancer product candidate.
Dr. Paul Lammers, Mirna’s CEO said: “Dr. Kim joins Mirna at an exciting time in our company’s growth, as we have just successfully initiated our MRX34 Phase I trial and are looking forward to further growth and maturation of our proprietary microRNA discovery platform and preclinical pipeline.”